Moneycontrol PRO
HomeNewsPoliticsOmicron is currently dominant COVID-19 variant in India: Govt

Omicron is currently dominant COVID-19 variant in India: Govt

With the reporting of Omicron, a highly mutated variant of SARSCoV-2 virus and its classification as a Variant of Concern (VoC) by the World Health Organization (WHO), the Union Ministry of Health revised its 'Guidelines for international arrivals', Mansukh Mandaviya said in a written reply.

February 08, 2022 / 17:30 IST
Union Health Minister Mansukh Mandaviya. (File image)

Omicron variant is the dominant variant in the country presently and the current surge of COVID-19 cases in the country is showing a sustained declining trend since January 21, Union Health Minister Mansukh Mandaviya informed the Rajya Sabha on Tuesday.

With the reporting of Omicron, a highly mutated variant of SARSCoV-2 virus and its classification as a Variant of Concern (VoC) by the World Health Organization (WHO), the Union Ministry of Health revised its 'Guidelines for international arrivals', Mandaviya said in a written reply.

"Omicron variant is the dominant variant in the country presently. The current surge of COVID-19 cases in the country is showing a sustained declining trend since January 21, 2022,” he said.

Following a risk based approach, provisions for mandatory pre-departure and post arrival RT-PCR testing on day 8th of arrival and a mandatory home quarantine for 7 days have been made in the present guidelines for all international travellers to India.

Follow our LIVE blog on Budget Session of Parliament

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The Ministry of Health continues to provide technical guidance for managing various aspects of COVID-19 including containment and surveillance, testing, clinical management protocols, post-COVID sequale, etc., the minister said.

The clinical management protocols have also been disseminated under the Ministry of Health’s Center of Excellence initiative for all states in collaboration with AIIMS, Delhi and Indian Medical Association.

Besides regular review meetings at the level of Union Health Minister with all relevant stakeholders including subject experts, review meetings with states and UTs through video conferencing have been conducted regularly to review preparedness and response measures to address COVID-19 pandemic, he said.

States and UTs have been advised to undertake several activities which include strict monitoring of International travellers in the community, contact tracing of positive individuals and follow up for 14 days, genome sequencing of positive samples through INSACOG Labs in a prompt manner, continued monitoring of areas where cluster of positive cases emerge and further strengthening of COVID-19 testing infrastructure.

They have been advised to ensure preparedness of health infrastructure (availability of ICU, oxygen supported beds, ventilators, etc.,) and upgrading health infrastructure under ECRP-II including in rural areas and for pediatric cases, commissioning all PSA plants, ensuring COVID-19 vaccination for the eligible population and ensuring adherence to COVID Appropriate Behaviour.

The Union Health Ministry continues to provide support to states and UTs to enhance preparedness and response capacities against COVID-19 and other public health emergencies.

Funding support is also provided to states and UTs through National Health Mission, State Disaster Response Funds (SDRF) and Emergency COVID-19 Response and Preparedness packages. Under ECRP Phase II, a package of Rs 23,123 crore (with Rs. 15,000 Cr as Central Component) has been approved.

Of this, as on 31st January 2022, funds to the tune of Rs 7245.95 crore have been released to states and UTs as part of central component to strengthen health infrastructure to manage any surge in cases, Mandaviya stated.

PTI
first published: Feb 8, 2022 05:28 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347